GeneProof Launches CMV IVDR Assay on myCROBE System for Transplant Diagnostics
GeneProof has launched the Cytomegalovirus MC PCR Kit under EU IVDR regulations on its myCROBE platform, enhancing transplant diagnostics. This development is pivotal for improving pathogen detection in immunocompromised patients.
Theia Market Signal Identification - AI Assisted
GeneProof has made the Cytomegalovirus (CMV) MC PCR Kit available under the European Union's In Vitro Diagnostic Regulation (IVDR), specifically on the myCROBE platform. This launch supports the line of Immunocompromised/Transplant (IT) PCR assays, which allows for simultaneous detection of multiple key viruses relevant in transplant care.
The myCROBE system enables sample-to-answer automation and customization of patient panels. These advancements follow GeneProof's 2025 announcement regarding the improvement of extraction methods and the availability of Sexually Transmitting Infections (STI) assays for the same platform. The expanded menu enhances laboratories' capabilities in managing complex infections, crucial for patient outcomes in transplant settings.
Comments